Researchers Find Strong Association Between TERT Antigens and Elevated B Cells in Head and Neck Cancer
|
Moores Cancer Center Solid Tumor Therapeutics Research Program member Dr. Maurizio Zanetti has been featured in ENT Today for his recent research on the relationship between an antigen produced in tumor cells and white blood cell levels. Read More»
|
|
|
Moores Cancer Center Chicago Social
|
Attending ASCO’s annual meeting in Chicago? Join the Moores Cancer Center Chicago Social, hosted by MCC Director Joseph Califano, MD on Sunday, June 4, 2023 at the Vu Rooftop. Please RSVP for an evening of fun to enjoy top-notch drinks, bites, and sweeping views with Moores alumni, former colleagues, and current researchers, clinicians, and physician-scientists and trainees. As new Director, Dr. Califano will present his vision for the future of Moores Cancer Center. The Vu Rooftop is conveniently located next door to McCormick Place. RSVP Now»
|
Call for Abstracts – 16th Annual AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
|
This conference will bring together professionals from industry, academic, government, and the community to promote the exchange of novel ideas, discuss the latest findings, and stimulate development of new research on cancer health disparities. The deadline to submit an abstract for the conference is June 13, 2023. Read More»
|
American Association of Cancer Research (AACR) Scientific Achievement Awards and Lectureships: Now Open for Nominations!
|
Several AACR awards and lectureships are now open for nominations and due on June 30th and September 15. Read More»
|
|
|
May 24, 2023
Moores Cancer Center, Comer Commons and Zoom
|
May 30, 2023
Leichtag Biomedical Research Building Room 107
|
|
|
NCI Cancer Prevention Fellowship Program
|
Applications for this postdoctoral fellowship program are open through August 1, 2023.
|
| Cancer Research, Training, and Education Coordination (CRTEC) at Moores has identified a number of high school and undergraduate students who want to volunteer this summer to do cancer-related research.
|
- 20–30 hours per week
- 4–6 weeks this summer
|
For more information, please contact Amy Spilkin, PhD
|
|
|
Applications for KL2 Mentored Career Development Award Now Open!
|
The ACTRI KL2 award is a mentored career development award that provides up to $120K towards salary, plus benefits, along with $25K per year in research funds. Successful applicants will receive up to three years of support. Applications for this program are open through August 15, 2023.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
Discovery Grants are intended to fund high-risk, high-reward innovative, collaborative research. Award will provide $250K for a period of 1 year. Targeted Grants are intended to fund innovative, translational, oncology-based projects that show promise of advancing to pre-clinical or clinical stages. Award will provide $500K for a period of 1–2 years. The Cure Prize is awarded to fund innovative ground-breaking ideas that will change the course of cancer care. Award will provide $1M for a period of 2–3 years.
Deadline: Tuesday, May 30, 2023
|
This funding opportunity will provide $100K in direct costs for three years. No part of the award may cover institutional overhead or other indirect costs.
Deadline: Tuesday, June 27, 2023
|
The Minnesota Ovarian Cancer Alliance will award up to $150,000 in November 2023 to support
research on the early detection of ovarian cancer.
Deadline: Friday, September 1, 2023
|
|
|
Nature
Scott M. Lippman (Cancer Control Program), Ludmil B. Alexandrov (Structural and Functional Genomics), Don W. Cleveland (Cancer Biology and Signaling)
|
Journal of Clinical Oncology
Shumei Kato, Structural and Functional Genomics
|
Journal of Clinical Oncology
Tiffany N. Tanaka, Hematologic Malignancies
|
|
|
MEKRAF-AST-101: A Phase 1/2a Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination with BGB3245 in Patients with Advanced Solid Tumors
PI: Gregory Daniels
|
CAAA617C12301: An Open-label, Randomized, Phase III Study Comparing 177LuPSMA617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
PI: James Randall
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
|
|
Help Celebrate Asian American, Native Hawaiian and Pacific Islander (AANHPI) Heritage Month
|
We warmly invite you to participate in Asian American, Native Hawaiian and Pacific Islander Heritage Month (AANHPI Month) and help celebrate the work and perspectives of not only Moores members and colleagues (at UC San Diego, SDSU, and LJI), but also UC San Diego Health and Health Sciences colleagues who identify as AANHPI. Please email Maritza Gomez at mag075@health.ucsd.edu your name, credentials, a photo, 1–2 sentences about your role, and something meaningful to you about your AANHPI culture and identity.
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to sjchristie@health.ucsd.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|
